Abstract: There is provided a transporter apparatus comprising a chassis (2) mounted upon at least two drive units (4). The drive units are arranged in parallel and define a space therebetween. The apparatus further comprises a motor (6) providing drive to at least one drive unit (4), and a lifting mechanism adapted to receive a load and move the load between the ground and a lifted position. The lifting mechanism comprises first and second guide bars (28), each guide bar having a first end attached to a drive unit (4) and a second end attached to the chassis (2). First and second lifting carriages (30) are slidingly mounted on a respective guide bar (28) and adapted to receive a portion of the load. First and second hydraulic rams (38) each have a first end attached to the chassis (2) and a second end attached to a respective lifting carriage (30).

Abstract: The present invention is directed to dosing, dosage regimens, formulations, unit dosage forms, and related, of a PARP7 inhibitor for the treatment of cancer. The present invention is also directed to methods of treating cancer by administering the PARP7 inhibitor in combination with an antibody that binds to PD-1.

Abstract: The present technology is directed to fluorinated alkylsulfonamide electrolyte salts with high solubility, conductivity, and electrochemical stability as well as batteries incorporating fluorinated alkylsulfonamide salts. In any aspect and/or embodiment herein of the present technology, the battery may include a separator disposed between the cathode and the anode. The separator may be a porous paper, porous ceramic, or porous polymer separator.

Abstract: The present technology is directed to a potassium metal battery, particularly a potassium metal secondary battery, that includes a cathode; an anode that includes potassium metal; and a non-aqueous electrolyte that includes a potassium salt as well as a solvent. The solvent may include dimethoxyethane, digylme, triglyme, tetraglyme, or a mixture of any two or more thereof.

Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: Methods and compositions for treating neuroendocrine tumors are disclosed.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: Methods and compositions for treating neuroendocrine tumors are disclosed.

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: The present invention encompasses the surprising finding that romidepsin can safely be administered to humans on an accelerated dosing schedule.

Abstract: The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).

Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.

Abstract: A system for delivering messages to a subscriber of a notification application. The system includes a plurality of available script templates defining formats for scripts, a message builder receiving application-specific data and building a script based on a previously unused script template, and merging the application-specific data with the script, and a message delivery module causing a human-understandable message to be delivered to the subscriber, the human-understandable message being generated from the script.

Abstract: A method for delivering a long term care message to a recipient includes gathering long term care information from a records repository and encoding at least some of the long term care information into predefined codes associated with predefined script segments. A script is generated using the script segments, and a human-understandable message is delivered to the recipient. A system for delivering a message related to long term care of a client serviced by an assisted living service provider includes an administration user interface enabling definition of script components that can be used to describe long term care of the client. A user associated with the assisted living service provider can record long term care information about the client. A script is generated using selected script components associated with the long term care information. A distributor module causes the script to be converted into a human-understandable message that is delivered to a message recipient.